Novacyt
S.A.
("Novacyt", the "Company" or the
"Group")
Notice of Half Year 2024 Results and
Investor Presentation
Paris, France, and Eastleigh and Manchester,
UK - 12 September 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM:
NCYT), an international molecular diagnostics company with a broad
portfolio of integrated technologies and services, announces that
it will report its unaudited financial results for the six months
ended 30 June 2024 on Thursday, 26 September 2024.
Investor webinar
An investor
webinar presentation by Lyn Rees, Chief Executive Officer, and
Steve Gibson, Chief Financial Officer, relating to the HY 2024
results will take place at 11.00am BST on Thursday, 26 September
2024.
The webinar is
open to all existing and potential investors, and will consist of a
presentation followed by a Q&A session, held on the Investor
Meet Company platform. Questions can be submitted pre-event via
your Investor Meet Company dashboard up until 9.00am the day before
the meeting or at any time during the live presentation.
Investors can sign
up for the webinar via:
https://www.investormeetcompany.com/novacyt-sa/register-investor
Investors who
already follow NOVACYT S.A. on the Investor Meet Company platform
will automatically be invited.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn Rees, Chief Executive
Officer
|
Via Walbrook
PR
|
|
Steve Gibson, Chief Financial
Officer
|
|
|
SP
Angel Corporate Finance LLP (Nominated Adviser and
Broker)
|
+44 (0)20
3470 0470
|
|
Matthew Johnson / Charlie Bouverat
(Corporate Finance)
Vadim Alexandre / Rob Rees
(Corporate Broking)
|
|
|
|
|
|
Deutsche Numis (Joint
Broker)
|
+44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick
Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR
(Financial PR & IR)
Stephanie Cuthbert / Paul McManus
/
Phillip Marriage / Alice
Woodings
|
+44 (0)20
7933 8780 or novacyt@walbrookpr.com
+44
(0)7796 794 663 / +44 (0)7980 541 893
+44
(0)7867 984 082 / +44 (0)7407 804 654
|
|
|
|
|
|
About Novacyt Group (www.novacyt.com)
Novacyt is an international
molecular diagnostics company providing a broad portfolio of
integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of
molecular assays and instrumentation to deliver workflows and
services that enable seamless end-to-end solutions from sample to
result across multiple sectors including human health, animal
health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical in vitro diagnostic products,
workflows and services focused on three therapeutic areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex winter
respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size selection DNA
sample preparation platforms and rapid PCR
machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
MyGo: real-time quantitative PCR
(qPCR) instruments
|
|
Research Use Only
|
Range of services for the research industry:
· Design,
manufacture, and supply of high-performance qPCR assays and
workflows for use in human health, agriculture, veterinary and
environmental, to support global health organisations and the
research industry
·
Pharmaceutical research services: whole genome sequencing (WGS) /
whole exome sequencing (WES)
|
Novacyt is headquartered in Vélizy
in France with offices in the UK (in Stokesley, Eastleigh and
Manchester), Singapore, the US and Canada and has a commercial
presence in over 65 countries. The Company is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock
Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com